PHATHOM PHARMACEUTICALS INC's ticker is PHAT and the CUSIP is 71722W107. A total of 85 filers reported holding PHATHOM PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is - and the average weighting 1.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $985,824 | -12.4% | 95,065 | +21.0% | 0.00% | – |
| Q2 2023 | $1,125,366 | +103.8% | 78,587 | +1.6% | 0.00% | – |
| Q1 2023 | $552,187 | -38.4% | 77,337 | -3.3% | 0.00% | – |
| Q4 2022 | $896,870 | +10.2% | 79,935 | +8.7% | 0.00% | – |
| Q3 2022 | $814,000 | +49.6% | 73,520 | +14.2% | 0.00% | – |
| Q2 2022 | $544,000 | -34.8% | 64,357 | +5.0% | 0.00% | – |
| Q1 2022 | $834,000 | -28.6% | 61,288 | +3.3% | 0.00% | – |
| Q4 2021 | $1,168,000 | -37.4% | 59,340 | +2.1% | 0.00% | – |
| Q3 2021 | $1,867,000 | +8.5% | 58,142 | +14.4% | 0.00% | – |
| Q2 2021 | $1,720,000 | +11.1% | 50,819 | +23.3% | 0.00% | – |
| Q1 2021 | $1,548,000 | +6.7% | 41,222 | -5.6% | 0.00% | – |
| Q4 2020 | $1,451,000 | -9.9% | 43,668 | -0.6% | 0.00% | – |
| Q3 2020 | $1,610,000 | +10.9% | 43,932 | -0.4% | 0.00% | – |
| Q2 2020 | $1,452,000 | +47.1% | 44,115 | +15.4% | 0.00% | – |
| Q1 2020 | $987,000 | +27.8% | 38,233 | +54.2% | 0.00% | – |
| Q4 2019 | $772,000 | – | 24,794 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Medicxi Ventures Management (Jersey) Ltd | 2,067,861 | $40,675,000 | 10.18% |
| FRAZIER MANAGEMENT LLC | 5,827,415 | $114,625,000 | 8.82% |
| Abingworth LLP | 1,203,135 | $23,606,000 | 5.72% |
| RA Capital Management | 3,115,008 | $61,272,000 | 1.08% |
| Avidity Partners Management LP | 1,896,000 | $37,294,000 | 0.79% |
| StepStone Group LP | 422,085 | $8,302,000 | 0.47% |
| Summit Rock Advisors, LP | 34,100 | $671,000 | 0.40% |
| Parkman Healthcare Partners LLC | 77,481 | $1,524,000 | 0.34% |
| Rhenman & Partners Asset Management AB | 186,210 | $3,624,000 | 0.24% |
| Ikarian Capital, LLC | 74,560 | $1,467,000 | 0.22% |